CYP2W1, CYP4F11 and CYP8A1 Polymorphisms and Interaction of CYP2W1 Genotypes with Risk Factors in Mexican Women with Breast Cancer

  • Cardenas-Rodriguez, N. (Section of Research and Graduate Studies, Instituto Politecnico Nacional) ;
  • Lara-Padilla, E. (Section of Research and Graduate Studies, Instituto Politecnico Nacional) ;
  • Bandala, C. (Section of Research and Graduate Studies, Instituto Politecnico Nacional) ;
  • Lopez-Cruz, J. (Service of Pathology, Clinica de Especialidades de la Mujer) ;
  • Uscanga-Carmona, C. (Service of Pathology, Clinica de Especialidades de la Mujer) ;
  • Lucio-Monter, P.F. (Laboratory of Pharmacology, Escuela Militar de Graduados de Sanidad, SEDENA) ;
  • Floriano-Sanchez, E. (Section of Research and Graduate Studies, Instituto Politecnico Nacional)
  • Published : 2012.03.31


Breast cancer (BCa) is the leading type of cancer in Mexican women. Genetic factors, such as single nucleotide polymorphisms (SNP) of P450 system, have been reported in BCa. In this report, and for the first time in the literature, we analyzed the rs3735684 (7021 G>A), rs11553651 (15016 G>T) and rs56195291 (60020 C>G) polymorphisms in the CYP2W1, 4F11 and 8A1 genes in patients with BCa and in healthy Mexican women to identify a potential association between these polymorphisms and BCa risk. Patients and controls were used for polymorphism analysis using an allelic discrimination assay with TaqMan probes and confirmed by DNA sequencing. Links with clinic-pathological characteristics were also analyzed. Statistical analysis was performed using the standard ${\chi}^2$ or Fisher exact test statistic. No significant differences were observed in the distributions of CYP2W1 (OR 8.6, 95%CI 0.43-172.5 P>0.05; OR 2.0, 95%CI 0.76-5.4, P>0.05) and CYP4F11 (OR 0.3, 95%CI 0.01-8.4 P>0.05) genotypes between the patients and controls. Only the CYP8A1 CC genotype was detected in patients with BCa and the controls. All polymorphism frequencies were in Hardy-Weinberg Equilibrium (HWE) in the controls (P>0.05). We found a significant association between BCa risk and smoking, use of oral contraceptives or hormonal replacement therapy (HRT), obesity, hyperglycemia, chronic diseases, family history of cancer and menopausal status in the population studied (P<0.05). Tobacco, oral contraceptive or HRT, chronic diseases and obesity or overweight were strongly associated with almost eight, thirty-five, nine and five-fold increased risk for BCa. Tobaco, obesity and hyperglycemia significantly increased the risk of BCa in the patients carrying variant genotypes of CYP2W1 (P<0.05). These results indicate that the CYP2W1 rs3735684, CYP4F11 rs11553651 and CYP8A1 rs56195291 SNPs are not a key risk factor for BCa in Mexican women. This study did not detect an association between the CYP2W1, 4F11 and 8A1 genes polymorphisms and BCa risk in a Mexican population. However, some clinico-pathological risk factors interact with CYP2W1 genotypes and modifies susceptibility to BCa.


  1. Abraham JE, Harrington P, Driver KE, et al (2009). Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res, 15, 2181-91.
  2. Bostick RM, Sprafka JM, Virnig BA, et al (1994). Predictors of cancer prevention attitudes and participation in cancer screening examinations. Prev Med, 23, 816-26.
  3. Calle EE, Rodríguez C, Walker Thurmond K, et al (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348, 1623-4.
  4. Cathcart MC, Reynolds JV, O'Byrne KJ, et al (2010). The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochim Biophys Acta, 1805, 153-66.
  5. Chiang CW, Yeh HC, Wang LH, et al (2006). Crystal structure of the human prostacyclin synthase. J Mol Biol, 364, 266-74.
  6. Choudhary D, Jansson I, Stoilov I, et al (2005). Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys, 436, 50-61.
  7. Cui X, Nelson DR, Strobel HW (2000). A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression, and genomic structural characterization. Genomics, 68, 161-6.
  8. DeWitt DL, Smith WL (1983). Purification of prostacyclin synthase from bovine aorta by immunoaffinity chromatography. Evidence that the enzyme is a hemoprotein. J Biol Chem, 258, 3285-93.
  9. Dhar M, Sepkovic DW, Hirani V, et al (2008). Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. J Lipid Res, 4, 612-24.
  10. Edler D, Stenstedt K, Ohrling K, et al (2009). The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study. Eur J Cancer, 45, 705-12.
  11. El Bayoumy, K (1992). Environmental carcinogens that may be involved in human breast cancer etiology. Chem Res Toxicol, 5, 585-90.
  12. Fleisher BS, Danon A (1999). IL-1alpha but not IL-1betainduced prostaglandin synthesis is inhibitedby corticotropinreleasing factor. Cytokine, 11, 239-43.
  13. Garrido LF, Lazcano Ponce EC, López CL, et al (1996). Age of natural menopause among women in Mexico City. Int J Gynaecol Obstet, 53, 159-66.
  14. Gervasini G, de Murillo SG, Ladero JM, et al (2010). CYP2W1 variant alleles in caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk. Pharmacogenomics, 11, 919-25.
  15. Gold EB, Bromberger J, Crawford S, et al (2001). Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol, 153, 865-74.
  16. Gonzalez FJ, Gelboin HV (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev, 26, 165-83.
  17. Guengerich FP, Wu ZL, Bartleson CJ (2005). Function of human cytochrome P450s: Characterization of the remaining orphans. Biochem Biophys Res Commun, 338, 465-9.
  18. Gupta RA, Tan J, Krause WF, et al (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci, 97, 13275-80.
  19. Gustafsson A, Hansson E, Kressner U, et al (2007). Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol, 46, 1107-12.
  20. Hellmold H, Rylander T, Magnusson M, et al (1998). Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J Clin Endocrinol Metab, 83, 886-95.
  21. Henderson IC (1993). Risk factors for breast cancer development. Cancer, 71, 2127-40.<2127::AID-CNCR2820711602>3.0.CO;2-2
  22. Honn KV, Cicone B, Skoff A (1981). Prostacyclin: a potent antimetastatic agent. Science, 212, 1270-2.
  23. Hsieh CC, Trichopoulus D, Katsouyanni K, et al (1990). Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer, 46, 796-800.
  24. Hunter DJ, Colditz GA, Hankinson SE, et al (2010). Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev, 19, 2496-502.
  25. Kajita S, Ruebel KH, Casey MB, et al (2005). Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol, 18, 221-7.
  26. Kalsotra A, Turman CM, Kikuta Y, et al (2004). Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol, 199, 295-304.
  27. Karlgren M, Miura S, Ingelman-Sundberg M (2005). Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol, 207, 57-61.
  28. Keith RL, Miller YE, Hudish TM, et al (2004). Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res, 64, 5897-904.
  29. Kivistoé KT, Kroemer HK, Eichelbaum M (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol, 40, 523-30.
  30. Lai JN, Wu CT, Chen PC, et al (2011). Increased risk for invasive breast cancer associated with hormonal therapy: a nationwide random sample of 65,723 women followed from 1997 to 2008. PLoS One, 6, e25183.
  31. Li CI, Daling JR, Malone KE, et al (2006). Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 15, 946-54.
  32. Li YC, Chiang CW, Yeh HC, et al. (2008). Structures of prostacyclin synthase and its complexes with substrate analog and inhibitor reveal a ligand-specific heme conformation change. J Biol Chem, 283, 2917-26.
  33. Li CI, Malone KE, Daling JR, et al (2008). Timing of menarche and first full-term birth in relation to breast cancer risk. Am J Epidemiol, 167, 230-9.
  34. Lorenzo Bermejo J, Hemminki K (2004). Familial association of histology specific breast cancers with cancers at other sites. Int J Cancer, 109, 430-5.
  35. Malfatti MA, Kulp KS, Knize MG, et al (1999). The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine metabolites in humans. Carcinogenesis, 20, 705-13.
  36. Mavaddat N, Dunning AM, Ponder BA, et al (2009). Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers Prev, 18, 255-9.
  37. McLemore TL, Hubbard WC, Litterst CL, et al (1998). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res, 48, 3140-7.
  38. Nebert DW, Ingelmann SM, Daly AK (1999). Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drugmetabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev, 31, 467-87.
  39. Nelson DR, Koymans L, Kamataki T, et al (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
  40. Newman B, Millikan RC, King MC (1997). Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev, 19, 69-79.
  41. Nishida CR, Lee M, De Montellano PR (2010). Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol, 78, 497-502.
  42. Pan SY, Johnson KC, Ugnat AM, et al (2004). Association of obesity and cancer risk in Canada. Am J Epidemiol, 159, 259-68.
  43. Pronk A, Ji BT, Shu XO, et al (2011). Physical activity and breast cancer risk in Chinese women. Br J Cancer, 105, 1443-50.
  44. Ruan KH, So SP, Zheng W, et al (2002). Solution structure and topology of the N-terminal membrane anchor domain of a microsomal cytochrome P450: prostaglandin I2 synthase. Biochem J, 368, 721-8.
  45. Scheen AJ, Beck E, De Flines J, et al (2011). Obesity, insulin resistance and type 2 diabetes: risk factors for breast cancer. Rev Med Liege, 66, 238-44.
  46. Sistema Nacional de Informacion en Salud, SSa. (2008) [].
  47. Smith G, Stanley LA, Sim E, et al (1995). Metabolic polymorphisms and cancer susceptibility. Cancer Surv, 25, 27-65.
  48. Speiser P (1996). Familial ovarian carcinoma. Wien Med Wochenschr, 146, 10-13.
  49. Suh S, Kim KW (2011). Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J, 35, 193-8.
  50. Tan BS, Tiong KH, Muruhadas A, et al (2011). CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5- fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther, 10, 1982-92.
  51. Tong BJ, Tan J, Tajeda L, et al (2000). Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor delta in human endometrial adenocarcinoma. Neoplasia, 2, 483-90.
  52. Torres Mejía G, Cupul Uicab LA, Allen B, et al (2005). Comparative study of correlates of early age at menarche among Mexican and Egyptian adolescents. Am J Hum Biol, 17, 654-8.
  53. Ullrich V, Castle L, Weber P (1981). Spectral evidence for the cytochrome P450 nature of prostacyclin synthetase. Biochem Pharmacol, 30, 2033-6.
  54. Uno Y, Matsuno K, Nakamura C, et al (2011). Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. J Vet Med Sci, 73, 487-90.
  55. Vigneri P, Frasca F, Sciacca L, et al. (2006). Obesity and cancer. Nutr Metab Cardiovasc Dis, 16, 1-7.
  56. Von Schoultz E, Johansson H, Wilking N, et al. (1995). Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol, 13, 430-4.
  57. Wang LH, Chen L (1996). Organization of the gene encoding human prostacyclin synthase. Biochem. Biophys Res Commun, 226, 631-7.
  58. Windmill, KF, McKinnon RA, Zhu X, et al. (1997). The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res, 376, 153-60.
  59. World Health Report. Geneva, WHO. (2008) [].
  60. Wu ZL, Sohl CD, Shimada T, et al (2006). Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol, 69, 2007-14.
  61. Yokoyama C, Yabuki T, Inoue H, et al (1996). Human gene encoding prostacyclin synthase (PTGIS): genomic organization, chromosomal localization, and promoter activity. Genomics, 36, 296-304.
  62. Yoshioka H, Kasai N, Ikushiro S, et al (2006). Enzymatic properties of human CYP2W1 expressed in Escherichia coli. Biochem Biophys Res Commun, 345, 169-74.
  63. Zeng L, Biernacka KM, Holly JM, et al (2010). Hyperglycaemia confers resistance tochemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer, 17, 539-51.

Cited by

  1. Relation of Alcohol/Tobacco use with Metastasis, Hormonal (Estrogen and Progesterone) Receptor Status and c-erbB2 Protein in Mammary Ductal Carcinoma vol.15, pp.14, 2014,
  2. CYP3A4 Expression in Breast Cancer and its Association with Risk Factors in Mexican Women vol.15, pp.8, 2014,
  3. Association of Histopathological Markers with Clinico-Pathological Factors in Mexican Women with Breast Cancer vol.16, pp.18, 2016,
  4. Identification of Genetic Polymorphisms of CYP2W1 in the Three Main Chinese Ethnicities: Han, Tibetan, and Uighur vol.44, pp.9, 2016,
  5. Cytochrome P450 2W1 (CYP2W1) – ready for use as the biomarker and drug target for cancer? vol.47, pp.10, 2017,